Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Rosiglitazone
Drug ID BADD_D02419
Description Rosiglitazone is an anti-diabetic drug in the thiazolidinedione class of drugs. It is marketed by the pharmaceutical company GlaxoSmithKline as a stand-alone drug (Avandia) and in combination with metformin (Avandamet) or with glimepiride (Avandaryl). Like other thiazolidinediones, the mechanism of action of rosiglitazone is by activation of the intracellular receptor class of the peroxisome proliferator-activated receptors (PPARs), specifically PPARγ. Rosiglitazone is a selective ligand of PPARγ, and has no PPARα-binding action. Apart from its effect on insulin resistance, it appears to have an anti-inflammatory effect: nuclear factor kappa-B (NFκB) levels fall and inhibitor (IκB) levels increase in patients on rosiglitazone. Recent research has suggested that rosiglitazone may also be of benefit to a subset of patients with Alzheimer's disease not expressing the ApoE4 allele. This is the subject of a clinical trial currently underway.
Indications and Usage Rosiglitazone is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Marketing Status Not Available
ATC Code A10BG02
DrugBank ID DB00412
KEGG ID D08491
MeSH ID D000077154
PubChem ID 77999
TTD Drug ID Not Available
NDC Product Code Not Available
Synonyms Rosiglitazone | Rosiglitazone Maleate | 5-((4-(2-Methyl-2-(pyridinylamino)ethoxy)phenyl)methyl)-2,4-thiazolidinedione-2-butenedioate | Avandia | BRL 49653 | BRL-49653 | BRL49653
Chemical Information
Molecular Formula C18H19N3O3S
CAS Registry Number 122320-73-4
SMILES CN(CCOC1=CC=C(C=C1)CC2C(=O)NC(=O)S2)C3=CC=CC=N3
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Cerebral atrophy17.11.01.0010.000501%Not Available
Cerebral haemorrhage24.07.04.001; 17.08.01.003--Not Available
Cerebral infarction24.04.06.002; 17.08.01.0040.010513%Not Available
Cerebral ischaemia24.04.06.003; 17.08.01.0050.000901%
Cerebral thrombosis24.01.04.003; 17.08.01.0060.000400%Not Available
Cerebrovascular accident24.03.05.001; 17.08.01.0070.356238%
Cerebrovascular disorder24.03.05.002; 17.08.02.0020.001175%Not Available
Chest discomfort22.02.08.001; 08.01.08.019; 02.02.02.009--Not Available
Chest pain22.02.08.003; 08.01.08.002; 02.02.02.0110.064680%Not Available
Cholangiocarcinoma16.07.01.002; 09.04.02.0090.000052%Not Available
Cholelithiasis09.03.01.002--Not Available
Chromaturia20.02.01.002--
Chronic lymphocytic leukaemia16.01.06.001; 01.10.06.001--Not Available
Chronic obstructive pulmonary disease22.03.01.0070.001358%Not Available
Circulatory collapse24.06.02.001--Not Available
Coagulopathy01.01.02.001--Not Available
Coma17.02.09.001--Not Available
Confusional state19.13.01.001; 17.02.03.005--
Constipation07.02.02.001--
Coordination abnormal17.02.02.004--Not Available
Cor pulmonale24.08.03.001; 22.06.01.003; 02.05.03.0010.000653%Not Available
Coronary artery disease24.04.04.006; 02.02.01.0010.334111%Not Available
Coronary artery occlusion24.04.04.013; 02.02.01.0060.013717%Not Available
Coronary artery stenosis02.02.01.010; 24.04.04.0170.002803%Not Available
Coronary artery thrombosis24.01.05.002; 02.02.01.0070.000261%Not Available
Cough22.02.03.001--
Deafness04.02.01.001--Not Available
Death08.04.01.001--
Decreased activity19.11.01.002; 08.01.01.0060.001101%Not Available
Delirium19.13.02.001--
The 4th Page    First    Pre   4 5 6 7 8    Next   Last    Total 19 Pages